Global psoriasis market size was valued at USD 31.68 billion in 2024 and is projected to reach USD 64.06 billion by 2032, with a CAGR of 9.20% during the forecast period of 2025 to 2032.

Psoriasis is a chronic, immune-mediated skin disease that affects millions of people worldwide, characterized by red, scaly patches that often cause discomfort and psychological distress. The condition is not only a dermatological concern but also a systemic disease that may be associated with psoriatic arthritis, cardiovascular complications, and metabolic disorders. Over the past decade, the psoriasis market has experienced significant transformation, driven by scientific breakthroughs, better understanding of immunopathogenesis, and increased availability of biologics and targeted therapies. The global market is expanding as healthcare providers, pharmaceutical companies, and patients increasingly seek advanced treatment options that provide long-term disease control, improved safety, and enhanced quality of life.

Download now:  https://www.databridgemarketresearch.com/reports/global-psoriasis-market

Market Trends

The psoriasis market is undergoing rapid changes due to several key trends. One of the most notable is the shift from traditional systemic therapies and topical treatments toward biologics and targeted small molecule drugs. Biologics such as TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors have become first-line choices for moderate to severe cases, reflecting the growing preference for therapies with better efficacy and durability.

Another trend shaping the market is the rising focus on personalized medicine. Pharmaceutical companies are investing in biomarker research and precision diagnostics to match patients with the most effective therapies, thereby improving treatment outcomes and minimizing adverse effects.

Digital health technologies are also entering the psoriasis landscape. Mobile applications and teledermatology platforms are improving patient monitoring, adherence, and physician-patient engagement. Additionally, awareness campaigns and patient advocacy groups are playing a crucial role in reducing stigma and encouraging early diagnosis and treatment adoption.

The competitive landscape is intensifying, with established pharmaceutical giants and biotech firms alike expanding their psoriasis portfolios. Pipeline drugs targeting new immune pathways and novel administration methods, such as oral therapies and injectables with extended dosing intervals, are expected to further transform the treatment paradigm.

Market Size

The global psoriasis market has reached significant value in recent years due to the rising prevalence of the condition and the availability of innovative therapies. The disease affects approximately 2–3% of the global population, making it a substantial healthcare concern. As healthcare spending increases and access to specialty drugs expands in both developed and emerging economies, the market size continues to grow.

The biologics segment contributes the largest share of revenue, given the high cost and strong demand for advanced therapies. Topical treatments and conventional systemic agents remain widely used, especially in mild cases and in regions with limited access to expensive biologics. Market expansion is also fueled by an increasing number of patients seeking medical intervention, driven by greater awareness of the long-term impact of untreated psoriasis on overall health and well-being.

Market Share

Within the psoriasis market, biologics dominate market share due to their effectiveness in managing moderate to severe psoriasis. Key pharmaceutical players, including AbbVie, Novartis, Amgen, Johnson & Johnson, Eli Lilly, and UCB, hold significant positions in the global landscape. AbbVie’s Humira and Skyrizi, Novartis’ Cosentyx, and Johnson & Johnson’s Tremfya are leading biologics that generate multi-billion-dollar revenues annually.

Although biologics capture the largest share, topical treatments such as corticosteroids, vitamin D analogs, and combination therapies continue to maintain strong usage rates, particularly among patients with mild to moderate forms of psoriasis. The systemic drug category, including methotrexate, cyclosporine, and acitretin, retains relevance but faces reduced market share due to the superior efficacy and safety profile of newer biologics.

Regional distribution of market share shows North America and Europe leading in terms of sales, primarily due to high healthcare spending, favorable reimbursement policies, and strong adoption of biologic therapies. The Asia-Pacific region is emerging as a rapidly growing market with rising patient awareness, improving healthcare infrastructure, and broader access to innovative treatments.

Market Growth

The psoriasis market is poised for steady growth in the coming years. Increasing prevalence, expanding treatment options, and rising healthcare expenditure are major drivers of this upward trajectory. The market is also benefiting from expanding indications for biologics and pipeline drugs that offer novel mechanisms of action.

Market growth is strongly supported by the surge in R&D investments. Pharmaceutical companies are exploring next-generation biologics, biosimilars, and oral therapies that promise improved safety profiles and better patient convenience. The introduction of biosimilars in particular is expected to accelerate market penetration by making advanced therapies more affordable and accessible.

Additionally, the growing recognition of psoriasis as a systemic disease with multiple comorbidities is pushing healthcare providers to adopt comprehensive management strategies, leading to greater demand for effective and long-term treatments. Regulatory approvals for new drugs and increasing healthcare reforms in emerging economies are also boosting overall market expansion.

Market Demand

Demand for psoriasis treatments continues to rise globally as patients increasingly seek therapies that not only control symptoms but also improve long-term quality of life. The preference is shifting toward biologics and oral targeted therapies that provide faster onset, longer remission periods, and reduced risk of side effects compared to older treatments.

Rising awareness campaigns by healthcare organizations and patient advocacy groups have significantly contributed to increased treatment-seeking behavior. Moreover, the rise in urbanization, stress, and lifestyle-related risk factors is leading to a higher incidence of psoriasis, further fueling demand.

Healthcare providers are also adopting integrated approaches to address both dermatological and systemic complications of the disease, creating opportunities for therapies that target comorbid conditions such as psoriatic arthritis, cardiovascular diseases, and metabolic syndrome. Demand is particularly strong in North America and Europe, while Asia-Pacific is showing rapid acceleration as healthcare access improves.

Browse More Reports:

Asia-Pacific Automotive Refinish Coatings Market
California Biostimulants Market
Europe Biostimulants Market
Middle East and Africa Vegetables and Fruits Market
South America Biostimulants Market
India Non-Stick Cookware Market
Europe Mezcal Market
Africa Sexual Wellness Market
Europe Personal Care Contract Manufacturing Market
Asia-Pacific Instant Noodles Market
Asia-Pacific Maintenance Repair and Operations (MRO) Market
Global 3D Glasses Market
Global Airport Security Market
Global Antidepressants Market
Global Augmented Reality (AR) and Mixed Reality (MR) Market

Market Future Insights

Looking ahead, the psoriasis market is expected to witness substantial evolution. Biologics and targeted oral therapies will remain the cornerstone of treatment, but increasing competition and the entry of biosimilars will reshape pricing dynamics and expand patient accessibility. The future will likely see more personalized therapies that tailor treatment regimens to individual patient profiles using genetic, molecular, and clinical data.

Digital health tools, including wearable devices and telemedicine platforms, are anticipated to play a significant role in monitoring disease activity, improving adherence, and enabling data-driven care. Pharmaceutical innovation will focus on improving dosing schedules, enhancing safety, and expanding indications for existing therapies.

The Asia-Pacific region is projected to be the fastest-growing market, driven by rising healthcare investments, government initiatives, and an expanding patient base. North America and Europe will continue to dominate in terms of revenue, but pricing pressures and competition from biosimilars may challenge the dominance of established players.

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research

US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975

Email:- corporatesales@databridgemarketresearch.com

Psoriasis Market, Psoriasis Market Trends, Psoriasis Market Growth, Psoriasis Market Demand, Psoriasis Market Size, Psoriasis Market Scope, Psoriasis Market Insights, Psoriasis Market Analysis,